Effect of postchemotherapy nausea and vomiting on health-related quality of life
Effect of postchemotherapy nausea and vomiting on health-related quality of life
复制标题
DOI：
10.1007/s005200050078
复制
发表时间：
1997-07-01
影响因子：
3.1
通讯作者：
Pater, J
中科院分区：
文献类型：
--
作者：
Osoba, D;Zee, B;Pater, J
本研究旨在评估接受中度或高度致吐化疗的患者化疗后恶心呕吐（PCNV）对健康相关生活质量（HQL）的影响。研究样本包括832名未经化疗的癌症患者，这些患者接受中度或高度致吐化疗，作为新止吐药多中心试验的一部分。患者在化疗前（基线）和化疗后1周（第8天）和2-4周完成自我报告的欧洲研究与癌症组织（EORTC：）核心生活质量问卷（QLQ-C30）。他们还完成了化疗后5-7天的自我报告恶心和呕吐（NV）日记。为了确定PCNV对HQL的影响，计算QLQ-C30中每个领域和症状的基线和第8天HQL评估之间的评分变化，并在4个患者亚组中进行比较：既有恶心又有呕吐的患者、有恶心但无呕吐的患者、无恶心但有呕吐的患者以及既无恶心也无呕吐的患者。与既无恶心也无呕吐的组相比，既有恶心又有呕吐的组在身体、认知和社会功能、总体生活质量、疲劳、厌食、失眠和呼吸困难方面表现出统计学显著性差（0.0001 < P < 0.05），只有恶心但没有呕吐的患者比同时有恶心和呕吐的患者功能和症状的恶化程度要轻，呕吐严重程度增加与1-2次呕吐相比，2次以上呕吐仅与总体生活质量和厌食恶化相关（0.0001 < P < 0.01），化疗后2-4周，所有HQL评分均恢复至基线水平或优于基线，PCNV对几个生活质量领域产生不利影响，但只有恶心的患者比同时伴有恶心和呕吐的患者经历的HQL破坏程度更低。呕吐1-2次的患者经历的HQL破坏程度与呕吐2次以上的患者几乎相同。
The purpose was to measure the effects of postchemotherapy nausea and vomiting (PCNV) on health-related quality of life (HQL) in patients receiving either moderately or highly emetogenic chemotherapy. The study sample consisted of 832 chemotherapy-naive patients with cancer who received either moderately or highly emetogenic chemotherapy as part of multicenter trials of new antiemetics, The patients completed the self-report European Organization for Research and Cancer (EORTC:) core Quality of Life Questionnaire (QLQ-C30) before chemotherapy (baseline) and 1 week (day 8) and 2-4 weeks after chemotherapy. They also completed a self-report nausea and vomiting (NV) diary for 5-7 days after chemotherapy. To determine the effects of PCNV on HQL, the change in scores between the baseline and day 8 HQL assessments was calculated for each domain and symptom in the QLQ-C30 and compared in four subgroups of patients: those with both nausea and vomiting, those with nausea but no vomiting, those with no nausea but with vomiting, and those with neither nausea nor vomiting. The group with both nausea and vomiting showed statistically significantly worse physical, cognitive and social functioning, global quality of life, fatigue, anorexia, insomnia and dyspnea as compared to the group with neither nausea nor vomiting (0.0001 < P < 0.05), Patients with only nausea but no vomiting tended to have less worsening in functioning and symptoms than those having both nausea and vomiting, Increased severity of vomiting (> 2 episodes) was associated with worsening of only global quality of life and anorexia as compared with 1-2 episodes of vomiting (0.0001 < P < 0.01), By 2-4 weeks after chemotherapy all HQL scores had either returned to their baseline levels or were better than baseline, PCNV adversely affects several quality-of-life domains, but patients with only nausea experience less disruption than do those with both nausea and vomiting, Patients with 1-2 episodes of vomiting experience almost the same degree of disruption of HQL as do patients with more than 2 episodes of vomiting.